Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.09% | 34.48 | 0.9% | $1196.77m | |
| JNJ | Johnson & Johnson | 1.58% | 143.20 | 0.7% | $1130.33m | |
| BMY | Bristol-Myers Squibb Co. | 2.05% | 60.35 | 1.0% | $997.01m | |
| MRK | Merck & Co., Inc. | 0.66% | 79.30 | 0.7% | $854.78m | |
| ABBV | AbbVie, Inc. | 0.75% | 99.62 | 1.9% | $817.19m | |
| LLY | Eli Lilly & Co. | 2.06% | 167.24 | 1.1% | $713.46m | |
| AZN | AstraZeneca Plc | 1.20% | 54.45 | 1.2% | $304.74m | |
| RPRX | Royalty Pharma Plc | 0.20% | 45.82 | 0.1% | $253.17m | |
| VXRT | Vaxart, Inc. | -13.16% | 6.40 | 0.0% | $194.99m | |
| NVS | Novartis AG | 1.05% | 88.49 | 0.2% | $162.08m | |
| GSK | GlaxoSmithKline Plc | -0.22% | 41.13 | 0.2% | $122.26m | |
| RGEN | Repligen Corp. | 0.92% | 127.81 | 7.2% | $121.24m | |
| NVO | Novo Nordisk A/S | -0.36% | 66.12 | 0.1% | $94.49m | |
| RETA | Reata Pharmaceuticals, Inc. | 2.37% | 161.59 | 3.4% | $89.79m | |
| SNY | Sanofi | 0.91% | 52.09 | 0.2% | $80.85m |
Company Profile
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.